JP2009545756A - タンパク質凝集を予測し凝集阻害物質を設計する方法 - Google Patents

タンパク質凝集を予測し凝集阻害物質を設計する方法 Download PDF

Info

Publication number
JP2009545756A
JP2009545756A JP2009523338A JP2009523338A JP2009545756A JP 2009545756 A JP2009545756 A JP 2009545756A JP 2009523338 A JP2009523338 A JP 2009523338A JP 2009523338 A JP2009523338 A JP 2009523338A JP 2009545756 A JP2009545756 A JP 2009545756A
Authority
JP
Japan
Prior art keywords
protein
aggregation
peptide
peptide sequence
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009523338A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009545756A5 (cg-RX-API-DMAC7.html
Inventor
カイ イェー コールホフ
ヘスス スルド
ミケーレ ヴェンドルスコロ
Original Assignee
ロンザ バイオロジックス ピーエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロンザ バイオロジックス ピーエルシー filed Critical ロンザ バイオロジックス ピーエルシー
Publication of JP2009545756A publication Critical patent/JP2009545756A/ja
Publication of JP2009545756A5 publication Critical patent/JP2009545756A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
JP2009523338A 2006-08-04 2007-07-24 タンパク質凝集を予測し凝集阻害物質を設計する方法 Pending JP2009545756A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82155306P 2006-08-04 2006-08-04
PCT/GB2007/002789 WO2008015384A1 (en) 2006-08-04 2007-07-24 Method for predicting protein aggregation and designing aggregation inhibitors

Publications (2)

Publication Number Publication Date
JP2009545756A true JP2009545756A (ja) 2009-12-24
JP2009545756A5 JP2009545756A5 (cg-RX-API-DMAC7.html) 2010-09-09

Family

ID=38573441

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523338A Pending JP2009545756A (ja) 2006-08-04 2007-07-24 タンパク質凝集を予測し凝集阻害物質を設計する方法

Country Status (11)

Country Link
US (1) US8290713B2 (cg-RX-API-DMAC7.html)
EP (1) EP2047393A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009545756A (cg-RX-API-DMAC7.html)
KR (1) KR20090047470A (cg-RX-API-DMAC7.html)
CN (1) CN101501694B (cg-RX-API-DMAC7.html)
AU (1) AU2007280282B2 (cg-RX-API-DMAC7.html)
CA (1) CA2657847A1 (cg-RX-API-DMAC7.html)
EA (1) EA016884B1 (cg-RX-API-DMAC7.html)
IL (1) IL196551A (cg-RX-API-DMAC7.html)
SG (1) SG173405A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008015384A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170094798A (ko) * 2015-01-06 2017-08-21 노쓰 캐롤라이나 스테이트 유니버시티 이종 단백질 생성을 최적화하기 위한 리보좀 역학 모델링

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
GB2455102A (en) * 2007-11-28 2009-06-03 Cambridge Entpr Ltd Protein Aggregation Prediction Systems
WO2009128948A1 (en) 2008-04-17 2009-10-22 Peptimmune, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
CN110187119B (zh) * 2008-10-31 2022-07-29 耶鲁大学 子痫前期检测和治疗的方法和组合物
JP2013508308A (ja) * 2009-10-23 2013-03-07 ガーバン インスティテュート オブ メディカル リサーチ 修飾可変ドメイン分子、ならびにその産生および使用方法
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
FI20105629A0 (fi) * 2010-06-03 2010-06-03 Estaja Oy Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120108904A1 (en) * 2010-10-20 2012-05-03 Yong Ma Cleaner for endoscope
CN103772487B (zh) * 2012-10-24 2015-11-25 国家纳米科学中心 一种抑制人胰淀素聚集或毒性的多肽、试剂及其应用
US9618524B2 (en) * 2014-03-26 2017-04-11 Plaxgen Inc. Method, composition, isolation and identification of a plaque particle and related biomarker
CN104502219B (zh) * 2014-12-18 2017-09-29 江苏大学 一种淀粉样多肽聚集抑制剂及其抑制效果评估和验证方法
GB201600176D0 (en) * 2016-01-06 2016-02-17 Cambridge Entpr Ltd Method of identifying novel protein aggregation inhibitors based on chemical kinetics
WO2017127679A1 (en) * 2016-01-21 2017-07-27 Protein Dynamic Solutions Llc Method and system for spectral data analysis
MX2019000047A (es) * 2016-06-29 2019-07-04 Univ California Inhibidores peptídicos de la acumulación de alfa-sinucleína basados en estructuras.
CN106501550A (zh) * 2016-12-09 2017-03-15 江苏大学 基于原子力显微镜氨基酸影响鱼蛋白聚集行为的评价方法
CN111653310B (zh) * 2020-06-29 2023-06-20 北京大学深圳研究生院 含二硫键多肽的结构预测方法及装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004513873A (ja) * 1999-11-05 2004-05-13 アクソニックス，インコーポレイティド アミロイド、アミロイド様沈着物またはそれらのβ−シートリッチな病理前駆体への異常タンパク質折り畳みに関係する疾患の治療における生体内使用に適するペプチド類似物および模倣物
WO2005000288A2 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of protein aggregation disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325817D0 (en) * 2003-11-05 2003-12-10 Univ Cambridge Tech Method and apparatus for assessing polypeptide aggregation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004513873A (ja) * 1999-11-05 2004-05-13 アクソニックス，インコーポレイティド アミロイド、アミロイド様沈着物またはそれらのβ−シートリッチな病理前駆体への異常タンパク質折り畳みに関係する疾患の治療における生体内使用に適するペプチド類似物および模倣物
WO2005000288A2 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of protein aggregation disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5009011081; ＤＥ　ＧＲＯＯＴ　ＮＡＴＡＬＩＡ　ＳＡＮＣＨＥＺ: ＢＭＣ　ＳＴＲＵＣＴＵＲＡＬ　ＢＩＯＬＯＧＹ Ｖ５　Ｎ１８, 20050930, Ｐ１-１５, ＢＩＯＭＥＤ　ＣＥＮＴＲＡＬ　ＬＴＤ． *
JPN5009011082; ＰＡＷＡＲ　Ａ　Ｐ: ＪＯＵＲＮＡＬ　ＯＦ　ＭＯＬＥＣＵＬＡＲ　ＢＩＯＬＯＧＹ Ｖ３５０　Ｎ２, 20050708, Ｐ３７９-３９２ *
JPN6012062078; ＴＡＫＡＨＡＳＨＩ　Ｔｓｕｙｏｓｈｉ　ｅｔ　ａｌ．: 'Ｐｅｐｔｉｄｅ　ａｎｄ　Ｐｒｏｔｅｉｎ　Ｍｉｍｅｔｉｃｓ　Ｉｎｈｉｂｉｔｉｎｇ　Ａｍｙｌｏｉｄ　beta-Ｐｅｐｔｉｄｅ　Ａｇｇｒｅｇａｔｉｏｎ' Ａｃｃ．　Ｃｈｅｍ．　Ｒｅｓ． Ｖｏｌ．４１，Ｎｏ．１０, 200810, Ｐ．１３０９-１３１８ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170094798A (ko) * 2015-01-06 2017-08-21 노쓰 캐롤라이나 스테이트 유니버시티 이종 단백질 생성을 최적화하기 위한 리보좀 역학 모델링
KR102473180B1 (ko) 2015-01-06 2022-12-01 노쓰 캐롤라이나 스테이트 유니버시티 이종 단백질 생성을 최적화하기 위한 리보좀 역학 모델링

Also Published As

Publication number Publication date
AU2007280282B2 (en) 2012-02-02
EA200970180A1 (ru) 2009-08-28
WO2008015384A1 (en) 2008-02-07
US8290713B2 (en) 2012-10-16
IL196551A (en) 2013-01-31
AU2007280282A1 (en) 2008-02-07
HK1131239A1 (en) 2010-01-15
CN101501694B (zh) 2011-11-30
EP2047393A1 (en) 2009-04-15
EA016884B1 (ru) 2012-08-30
WO2008015384A8 (en) 2008-05-15
KR20090047470A (ko) 2009-05-12
CA2657847A1 (en) 2008-02-07
IL196551A0 (en) 2009-11-18
US20100160602A1 (en) 2010-06-24
CN101501694A (zh) 2009-08-05
SG173405A1 (en) 2011-08-29

Similar Documents

Publication Publication Date Title
US8290713B2 (en) Method for predicting protein aggregation and designing aggregation inhibitors
Man et al. Effects of all-atom molecular mechanics force fields on amyloid peptide assembly: the case of aβ16–22 dimer
Mo et al. Conformational ensemble of hIAPP dimer: insight into the molecular mechanism by which a green tea extract inhibits hIAPP aggregation
Maurer-Stroh et al. Exploring the sequence determinants of amyloid structure using position-specific scoring matrices
Sommer et al. Structure-guided isoform identification for the human transcriptome
Jana et al. Presence of a SARS-CoV‑2 Protein Enhances Amyloid Formation of Serum Amyloid A
Liu et al. Disclosing the mechanism of spontaneous aggregation and template-induced misfolding of the key hexapeptide (PHF6) of tau protein based on molecular dynamics simulation
Saravanan et al. On the conformational dynamics of β-amyloid forming peptides: A computational perspective
Fatafta et al. A brief history of amyloid aggregation simulations
Robinson et al. Are AMBER force fields and implicit solvation models additive? A folding study with a balanced peptide test set
Pujols et al. A3D 2.0 update for the prediction and optimization of protein solubility
JP2021531607A (ja) 中間体を特定する方法
Linh et al. Impact of Mutations at C‑Terminus on Structures and Dynamics of Aβ40 and Aβ42: A Molecular Simulation Study
Kardos et al. Phosphorylation as conformational switch from the native to amyloid state: Trp-cage as a protein aggregation model
Poboinev et al. The PentUnFOLD algorithm as a tool to distinguish the dark and the light sides of the structural instability of proteins
Wang et al. StaPep: an open-source toolkit for structure prediction, feature extraction, and rational design of hydrocarbon-stapled peptides
Rogne et al. Atomic-level structure characterization of an ultrafast folding mini-protein denatured state
Black et al. Evaluating calmodulin–protein interactions by rapid photoactivated cross-linking in live cells metabolically labeled with photo-methionine
Nayak et al. Robust anti-inflammatory activity of genistein against neutrophil elastase: a microsecond molecular dynamics simulation study
Liu et al. Computationally Designed Molecules Modulate ALS-Related Amyloidogenic TDP-43307–319 Aggregation
Zganec et al. Assembly of stefin B into polymorphic oligomers probed by discrete molecular dynamics
Jakubek et al. Polyglutamine Solution-State Structural Propensity Is Repeat-Length-Dependent
Javanmard et al. In-silico structural analysis of Heterocephalus glaber amyloid beta: an anti-Alzheimer's peptide
HK1131239B (en) Method for predicting protein aggregation and designing aggregation inhibitors
Hassan et al. Neurodegeneration through the lens of bioinformatics approaches: Computational mechanisms of protein misfolding

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100723

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130826